Search Results
Results found for "David M. Thal"
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
Here, the Schild plot becomes a diagnostic tool rather than a checkbox test: Slopes >1 often mean incomplete to Partial Agonists Partial agonists complicate things—they activate receptors but less effectively than
- Dr. Marta Filizola - Dr. GPCR Podcast
GPCR Podcast, we have none other than Dr. Marta Filizola!
- First AMA of 2026: GPCR Pharmacology, Biased Signaling & Mechanistic Clarity
grows, it becomes a searchable extension of Terry’s teaching — designed for repeated exposure rather than
- Dr. Juan José Fung - Dr. GPCR Podcast
Our guest is none other than Dr. Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.
- Unconventional GPCR-PKA Communication in the Hedgehog Pathway
Our first guest speaker is none other than Dr. Ben Myers!
- Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling
determine partner preference; or (iii) the dynamics of GPCR binding to different types of partners rather than
- Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with ...
Better known as GPCR, the fruitful research space has led to more than 700 approved drugs over previous
- GPCR Collaboration: From Models to Medicine
in academia or biotech, the future belongs to research groups that can orchestrate ecosystems rather than He treats modeling as part of a continuum rather than a separate discipline.
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
One potential solution is to develop analgesics that act at targets other than opioid receptors.
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
Hassard is a commercial leader with more than three decades of experience leading sales and marketing
- Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
A much smaller conformational change of helix VI upon activation than previously solved class A GPCR-Gi
- Understanding Orthosteric Binding: The Key to Drug Action
Unlocking the Secrets of Orthosteric Binding Understanding why some drugs bind better than others is
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
This is more than review, it’s readiness.
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
In less than a decade, nanobodies, or recombinant single-domain antibody fragments from camelids, have
- Dr. GPCR Spotlights Revvity’s pHSense™ Internalization Tools
A GPCR Internalization Tool Designed for Real Research Needs Built on more than two decade A GPCR Internalization
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
Clues that point to true multiple-site binding rather than two-stage GPCR biology: Disrupting G protein If the tracer binds faster than the displacer, early time points exaggerate tracer occupancy and underestimate
- Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than
- Structures of β 1-adrenergic receptor in complex with Gs and ligands of different efficacies
intermediate state complex comprising β1-AR and nucleotide-free Gs is more stable when binding a full agonist than
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
This Chemistry Tools session was more industry focused than those before, and Maria shared the floor
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
In fact, it is often costly, frustrating, and tortuous—and more often than not it ends in failure.
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
Six compounds showed more than 50% displacement of the radioligand at 10 µM concentration with compound
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
He has led teams that have filed more than 10 Investigational New Drug Applications (IND), as well as
- Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands..
However, our predictions were many folds shorter than those determined experimentally.
- C5aR2 receptor: The genomic twin of the flamboyant C5aR1
C5aR2 is a nonclassical GPCR that tailors immune cell activity potentially through β-arrestins rather than
- Delineation of GPR15 receptor-mediated Gα protein signaling profile in recombinant mammalian cell
The results show that the GPR15 receptor preferentially couples to Gi/o rather than other pathways in
- Comparative studies of AlphaFold, RoseTTAFold and Modeller: a case study involving the use of...
program's top-scored structure, Modeller had the smallest average modeling RMSD of 2.17 Å, which is better than
- Design and validation of recombinant protein standards for quantitative Western blot analysis of...
density obtained by quantitative Western blot were of the same order of magnitude but slightly higher than
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
AlphaFold2 outperformed homology models, achieving a 60% hit rate for compounds targeting TAAR1, more than
- GPCR Happy Hour – Boston, Sept 2025
GPCR Happy Hour is more than a social event.












